Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: International Conference on Prevention & Infection Control (ICPIC 2011)

Open Access Poster presentation

Fluoroquinolone (FQ) utilization in symptomatic bacteriuria (SB) due to E. coli and rate of FQ-resistant E. coli in a teaching psychiatric hospital

F Westphal12* and M Hittinger3

  • * Corresponding author: F Westphal

Author Affiliations

1 Dept of General and Geriatric Medicine, Hospital center-EPSAN, Strasbourg-Brumath, France

2 Bacteriology Laboratory, University Hospital, Strasbourg, France

3 Infection Control Unit, Hospital center-EPSAN, Strasbourg-Brumath, France

For all author emails, please log on.

BMC Proceedings 2011, 5(Suppl 6):P148  doi:10.1186/1753-6561-5-S6-P148

The electronic version of this article is the complete one and can be found online at:

Published:29 June 2011

© 2011 Westphal and Hittinger; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction / objectives

There are still very few data available on antibiotic utilization and bacterial resistance in the mental healthcare setting. The present study examined the extent of FQ utilization and the rate of FQ-resistant E. coli in SB in a 600-bed teaching psychiatric hospital.


SB data were reviewed by the Infection Control Unit over a 5-year survey and compared across two inpatient populations, namely patients in long-term care (LTC) geriatric wards (128 beds) and in acute general psychiatry (AGP) wards (470 beds).


Overall, 146 SB and 176 organisms were recorded in LTC wards vs. 336 and 376 in AGP wards, respectively. E. coli accounted for 55 % of urinary isolates in LTC wards vs. 68% in AGP wards (p<0.01). In AGP wards, there was no significant trend (χ²) in the year-to-year utilization of FQ for treating SB (range 60%>75%) as well as in the rate of FQ-resistant E. coli, rising from 12% to 15% over the study period. In contrast, a significant increase in the rate of FQ-resistant E. coli causing SB (from 11% to 50%, p<0.01) was seen in LTC wards over the study period and was concomitant of a linear decrease (r=0.90, p<0.05) in FQ utilization for treating SB in this setting. This increasing resistance rate could be explained in part by the high level of FQ utilization (74%) for treating SB in the LTC wards during the first year of the survey; yet other factors might be involved.


In this study, rate of FQ-resistant E. coli appeared relatively low in the AGP wards despite the extensive use of FQ. However, enhanced surveillance in LTC geriatric wards seems required because of the risk of emerging high rate of FQ-resistant E. coli in this setting.

Disclosure of interest

None declared.